Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 9, 2006, Pages 2957-2965

  Chung, Philip ^a   McNamara, Patrick J ^a   Campion, Jeffrey J ^b   Evans, Martin E ^b,c  

^a University of Kentucky   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c LEXINGTON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL GENE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BACTERIUM MUTANT; CORRELATION ANALYSIS; DRUG MECHANISM; GRLA GENE; MATHEMATICAL MODEL; MICROBIAL POPULATION DYNAMICS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PREDICTION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; WILD TYPE;

ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; STAPHYLOCOCCUS AUREUS;

EID: 33748677949     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00736-05     Document Type: Article

References (25)

1. Bouvier d'Yvoire, M. J. Y., and P. H. Maire. 1996. Dosage regimens of antibacterials: implications of a pharmacokinetic/pharmacodynamic model. Clin. Drug Investig. 11:229-239.
2. Burnham, K. P., and D. R. Anderson. 2002. Model selection and multimodel inference: a practical information-theoretic approach, 2nd ed. Springer, New York, N.Y.
3. Campion, J. J., P. Chung, P. J. McNamara, W. B. Titlow, and M. E. Evans. 2005. Pharmacodynamic modeling of levofloxacin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 49:2189-2199.
4. Campion, J. J., P. J. McNamara, and M. E. Evans. 2004. Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments. Antimicrob. Agents Chemother. 48:4733-4744.
5. Campion, J. J., P. J. McNamara, and M. E. Evans. 2005. Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 49:209-219.
6. Dayneka, N. L., V. Garg, and W. J. Jusko. 1993. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21:457-478.
7. Fisher, L. E., E. A. Ludwig, and W. J. Jusko. 1992. Pharmacoimmunodynamics of methylprednisolone: trafficking of helper T lymphocytes. J. Pharmacokinet. Biopharm. 20:319-331.
8. Fung-Tomc, J. C., E. Gradelski, L. Valera, B. Kolek, and D. P. Bonner. 2000. Comparative killing rates of fluoroquinolones and cell wall-active agents. Antimicrob. Agents Chemother. 44:1377-1380.
9. Gabrielsson, J., and D. Weiner. 2000. Pharmacokinetic/pharmacodynamic data analysis: concepts and applications, 3rd ed. Apotekarsocieteten, Stockholm, Sweden.
10. Gradelski, E., B. Kolek, D. Bonner, and J. C. Fung-Tomc. 2002. Bactericidal mechanism of gatifloxacin compared with other quinolones. J. Antimicrob. Chemother. 49:185-188.
11. Gradelski, E., L. Valera, B. Kolek, D. Bonner, and J. Fung-Tomc. 2001. Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams. Int. J. Antimicrob. Agents 18:43-48.
12. Gumbo, T., A. Louie, M. R. Deziel, L. M. Parsons, M. Salfinger, and G. L. Drusano. 2004. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis. 190:1642-1651.
13. Hiasa, H., D. O. Yousef, and K. J. Marians. 1996. DNA strand cleavage is required for replication fork arrest by a frozen topoisomerase-quinolone-DNA ternary complex. J. Biol. Chem. 271:26424-26429.
14. Jumbe, N., A. Louie, R. Leary, W. Liu, M. R. Deziel, V. H. Tam, R. Bachhawat, C. Freeman, J. Kahn, K. Bush, M. N. Dudley, M. H. Miller, and G. L. Drusano. 2003. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Investig. 112:275-285.
15. Jusko, W. J., and H. C. Ko. 1994. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin. Pharmacol. Ther. 56:406-419.
16. Khodursky, A. B., and N. R. Cozzarrelli. 1998. The mechanism of inhibition of topoisomerase IV by quinolone antibacterials. J. Biol. Chem. 273:27668-27677.
17. Lipsitch, M., and B. R. Levin. 1997. The population dynamics of antimicrobial chemotherapy. Antimicrob. Agents Chemother. 41:363-373.
18. Meagher, A. K., A. Forrest, A. Dalhoff, H. Stass, and J. J. Schentag. 2004. Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. Antimicrob. Agents Chemother. 48:2061-2068.
19. Mouton, J. W., and A. A. Vinks. 2005. Pharmacokinetic/pharmacodynamic modeling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics. The minimum inhibitory concentration versus stationary concentration. Clin. Pharmacokinet. 44:201-210.
20. Mouton, J. W., A. A. T. M. M. Vinks, and N. C. Punt. 1997. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob. Agents Chemother. 41:733-738.
21. Nelder, J. A., and R. Mead. 1965. A simplex method for function minimization. Computing J. 7:308-313.
22. Noble, C. G., F. M. Barnard, and A. Maxwell. 2003. Quinolone-DNA interaction: sequence-dependent binding to single-stranded DNA reflects the interaction within the gyrase-DNA complex. Antimicrob. Agents Chemother. 47:854-862.
23. Regoes, R. R., C. Wiuff, R. M. Zappala, K. N. Garner, F. Baquero, and B. R. Levin. 2004. Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob. Agents Chemother. 48:3670-3676.
24. van Griensven, J. M. T., W. J. Jusko, H. H. P. J. Lemkes, R. Kroon, C. J. Verhorst, and S. T. Chiang. 1995. Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes. Clin. Pharmacol. Ther. 58:631-640.
25. Willmott, C. J., S. E. Critchlow, I. C. Eperon, and A. Maxwell. 1994. The complex of DNA gyrase and quinolone drugs with DNA forms a barrier to transcription of RNA polymerase. J. Mol. Biol. 242:351-363.